comprehensive -WSS

comprehensive

author：fashion 2025-10-02 14:57:17 - browse：62597

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The Danish pharmaceutical company Novo Nordisk has shepherded all kinds of medical innovation in the 110 years since it was founded. But the booming success of its diabetes and obesity drug is unlike anything executives have seen before.

The company’s mid-year operating profit jumped from 37.5 billion Danish kroner in 2022 to 48.9 billion Danish kroner this year — “probably the strongest growth in the history of the company,” Chief Financial Officer Karsten Munk Knudsen said during an August earnings call. The 30% growth rate came from sales of semaglutide, which Novo Nordisk sells for diabetes under the name Ozempic and for obesity as Wegovy.

With its new blockbuster drug in hand, Novo Nordisk is valued higher than the entire economy of Denmark, where it’s based.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Change Healthcare cyberattack shows risk of industry consolidation

knowledge

WSS

Medicare Advantage isn’t working — for anyone

Americans' trust in science, scientist continues decline: Report

Doctor of U.S. President Joe Biden says he is fit for duty

Childhood vaccination ad campaign launches in the U.K.

SCOTUS to consider access to abortion pill mifepristone

Cholera vaccine supplies dangerously low, outbreaks surging

leisure time

comprehensive

knowledge

New air purifier tech could be key to improving indoor air quality

SCOTUS to consider access to abortion pill mifepristone

Affirmative action in medical school literally saved lives

Chemotherapy shortages won’t get better under Biden’s latest plan

Activists slam private health insurers over coverage restrictions

Childhood vaccination ad campaign launches in the U.K.

Alkermes shareholders re

Ohio train derailment: Experts on toxic chemical risks

Drug repurposing or repositioning? The language matters

'Vaccine

focus

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

The woman behind the Dana Farber

Patients' immediate access to test results puts radiologists in a bind

In diabetes hearing, Sanders takes on a new foe: food makers

Elisabeth Bik tackles the widespread issue of research misconduct

Readout Newsletter: Beam, Prozac, "TechBio" and more

focus

knowledge

hotspot

focus